Bilal Shaker

Dr. Bilal Shaker


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
MDMiraj ud din
Miraj ud din
AAAqel Albutti
Aqel Albutti
AUAsad Ullah
Asad Ullah
IIIsmail Ismail
Ismail Ismail
Sajjad AhmadSajjad Ahmad
Sajjad Ahmad
Muhammad Tahir ul QamarMuhammad Tahir ul Qamar
Muhammad Tahir ul Qamar
Antibiotic resistance (AR) is the result of microbes’ natural evolution to withstand the action of antibiotics used against them. AR is rising to a high level across the globe, and novel resistant strains are emerging and spreading very fast. Acinetobacter baumannii is a multidrug resistant Gram-negative bacteria, responsible for causing severe nosocomial infections that are treated with several broad spectrum antibiotics: carbapenems, β-lactam, aminoglycosides, tetracycline, gentamicin, impanel, piperacillin, and amikacin. The A. baumannii genome is superplastic to acquire new resistant mechanisms and, as there is no vaccine in the development process for this pathogen, the situation is more worrisome. This study was conducted to identify protective antigens from the core genome of the pathogen. Genomic data of fully sequenced strains of A. baumannii were retrieved from the national center for biotechnological information (NCBI) database and subjected to various genomics, immunoinformatics, proteomics, and biophysical analyses to identify potential vaccine antigens against A. baumannii. By doing so, four outer membrane proteins were prioritized: TonB-dependent siderphore receptor, OmpA family protein, type IV pilus biogenesis stability protein, and OprD family outer membrane porin. Immuoinformatics predicted B-cell and T-cell epitopes from all four proteins. The antigenic epitopes were linked to design a multi-epitopes vaccine construct using GPGPG linkers and adjuvant cholera toxin B subunit to boost the immune responses. A 3D model of the vaccine construct was built, loop refined, and considered for extensive error examination. Disulfide engineering was performed for the stability of the vaccine construct. Blind docking of the vaccine was conducted with host MHC-I, MHC-II, and toll-like receptors 4 (TLR-4) molecules. Molecular dynamic simulation was carried out to understand the vaccine-receptors dynamics and binding stability, as well as to evaluate the presentation of epitopes to the host immune system. Binding energies estimation was achieved to understand intermolecular interaction energies and validate docking and simulation studies. The results suggested that the designed vaccine construct has high potential to induce protective host immune responses and can be a good vaccine candidate for experimental in vivo and in vitro studies.

28 April 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
TAThamer Albekairi
Thamer Albekairi
AAAbdulrahman Alshammari
Abdulrahman Alshammari
MAMetab Alharbi
Metab Alharbi
AAAmal F. Alshammary
Amal F. Alshammary
Muhammad Tahir ul QamarMuhammad Tahir ul Qamar
Muhammad Tahir ul Qamar
Sajjad AhmadSajjad Ahmad
Sajjad Ahmad
Whipple’s disease is caused by T. whipplei, a Gram-positive pathogenic bacterium. It is considered a persistent infection affecting various organs, more likely to infect males. There is currently no licensed vaccination available for Whipple’s disease; thus, the development of a chimeric peptide-based vaccine against T. whipplei has the potential to be tremendously beneficial in preventing Whipple’s disease in the future. The present study aimed to apply modern computational approaches to generate a multi-epitope-based vaccine that expresses antigenic determinants prioritized from the core proteome of two T. whipplei whole proteomes. Using an integrated computational approach, four immunodominant epitopes were found from two extracellular proteins. Combined, these epitopes covered 89.03% of the global population. The shortlisted epitopes exhibited a strong binding affinity for the B- and T-cell reference set of alleles, high antigenicity score, nonallergenic nature, high solubility, nontoxicity, and excellent binders of DRB1*0101. Through the use of appropriate linkers and adjuvation with a suitable adjuvant molecule, the epitopes were designed into a chimeric vaccine. An adjuvant was linked to the connected epitopes to boost immunogenicity and efficiently engage both innate and adaptive immunity. The physiochemical properties of the vaccine were observed favorable, leading toward the 3D modeling of the construct. Furthermore, the vaccine’s binding confirmation to the TLR-4 critical innate immune receptor was also determined using molecular docking and molecular dynamics (MD) simulations, which shows that the vaccine has a strong binding affinity for TLR4 (−29.4452 kcal/mol in MM-GBSA and −42.3229 kcal/mol in MM-PBSA). Overall, the vaccine described here has a promising potential for eliciting protective and targeted immunogenicity, subject to further experimental testing.

21 November 2022 in Molecules
Verified
Journal Article
Open access
PDF file
KMKhalid miandad
Khalid miandad
AUAsad Ullah Ullah
Asad Ullah Ullah
KBKashif Bashir
Kashif Bashir
SKSaifullah Khan
Saifullah Khan
SASyed Ainul Abideen
Syed Ainul Abideen
Sajjad AhmadSajjad Ahmad
Sajjad Ahmad
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a human coronaviruses that emerged in China at Wuhan city, Hubei province during December 2019. Subsequently, SARS-CoV-2 has spread worldwide and caused millions of deaths around the globe. Several compounds and vaccines have been proposed to tackle this crisis. Novel recommended in silico approaches have been commonly used to screen for specific SARS-CoV-2 inhibitors of different types. Herein, the phytochemicals of Pakistani medicinal plants (especially Artemisia annua) were virtually screened to identify potential inhibitors of the SARS-CoV-2 main protease enzyme. The X-ray crystal structure of the main protease of SARS-CoV-2 with an N3 inhibitor was obtained from the protein data bank while A. annua phytochemicals were retrieved from different drug databases. The docking technique was carried out to assess the binding efficacy of the retrieved phytochemicals; the docking results revealed that several phytochemicals have potential to inhibit the SARS-CoV-2 main protease enzyme. Among the total docked compounds, the top-10 docked complexes were considered for further study and evaluated for their physiochemical and pharmacokinetic properties. The top-3 docked complexes with the best binding energies were as follows: the top-1 docked complex with a −7 kcal/mol binding energy score, the top-2 docked complex with a −6.9 kcal/mol binding energy score, and the top-3 docked complex with a −6.8 kcal/mol binding energy score. These complexes were subjected to a molecular dynamic simulation analysis for further validation to check the dynamic behavior of the selected top-complexes. During the whole simulation time, no major changes were observed in the docked complexes, which indicated complex stability. Additionally, the free binding energies for the selected docked complexes were also estimated via the MM-GB/PBSA approach, and the results revealed that the total delta energies of MMGBSA were −24.23 kcal/mol, −26.38 kcal/mol, and −25 kcal/mol for top-1, top-2, and top-3, respectively. MMPBSA calculated the delta total energy as −17.23 kcal/mol (top-1 complex), −24.75 kcal/mol (top-2 complex), and −24.86 kcal/mol (top-3 complex). This study explored in silico screened phytochemicals against the main protease of the SARS-CoV-2 virus; however, the findings require an experimentally based study to further validate the obtained results.

17 March 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
MAMetab Alharbi
Metab Alharbi
AAAbdulrahman Alshammari
Abdulrahman Alshammari
Abdullah F. AlAsmariAbdullah F. AlAsmari
Abdullah F. AlAsmari
SASaud Alharbi
Saud Alharbi
Muhammad Tahir ul QamarMuhammad Tahir ul Qamar
Muhammad Tahir ul Qamar
Sajjad AhmadSajjad Ahmad
Sajjad Ahmad
This study involved therapeutic targets mining for the extremely drug-resistant bacterial species called Alcaligenes faecalis, which is known to infect humans. The infections caused by this species in different parts of the human body have been linked with a higher degree of resistance to several classes of antibiotics. Meanwhile, alternate therapeutic options are needed to treat these bacterial infections in clinical settings. In the current study, a subtractive proteomics approach was adapted to annotate the whole proteome of Alcaligenes faecalis and prioritize target proteins for vaccine-related therapeutics design. This was followed by targeted protein-specific immune epitope prediction and prioritization. The shortlisted epitopes were further subjected to structural design and in silico validation of putative vaccines against Alcaligenes faecalis. The final vaccine designs were also evaluated for potential interaction analysis with human TLR-2 through molecular docking. Finally, the putative vaccines were subjected to in silico cloning and immune simulation approaches to ensure the feasibility of the target-specific vaccine constructs in further experimental designs.

24 August 2023 in Applied Biochemistry and Biotechnology
Verified
Journal Article
Closed access
PDF file
HRHibba Rashid
Hibba Rashid
AUAsad Ullah
Asad Ullah
Sajjad AhmadSajjad Ahmad
Sajjad Ahmad
SASalma Mohammed Aljahdali
Salma Mohammed Aljahdali
YWYasir Waheed
Yasir Waheed
MIMuhammad Irfan
Muhammad Irfan

21 October 2025
Verified
Book Chapter
Open access
PDF file
BSBilal Shaker
Bilal Shaker
Khaled BarakatKhaled Barakat
Khaled Barakat
Molecular docking has become a cornerstone in modern drug discovery, helping scientists predict how small molecules, or ligands, interact with target proteins. With the rise of artificial intelligence, particularly deep learning and generative models, traditional docking methods have been transformed. These AI-powered approaches not only boost accuracy but also dramatically reduce the time and cost of early-phase drug screening. This review explores how deep learning and generative AI are being applied to molecular docking simulations. Tools like AtomNet, DeepDock, KDEEP, and AutoDock Vina, when integrated with neural networks, have shown impressive improvements in predicting protein-ligand binding affinities compared to older docking methods. These AI models can rapidly screen massive chemical libraries, accelerating the identification of potential drug candidates. For instance, AtomNet, one of the first deep convolutional networks used in structure-based drug discovery, contributed to early drug leads for diseases like Ebola and cancer. AlphaFold, from DeepMind, has also revolutionized protein structure prediction, setting a new benchmark for accuracy. Beyond raw prediction power, these tools adapt over time. They learn from new data and minimizing human bias in compound selection. Their scalable architecture enables repeated simulations with increasing precision. This synergy of human intuition and AI precision marks a turning point in drug discovery. By using AI-driven molecular docking, researchers can now prioritize compounds more strategically, paving the way for faster, more efficient development of new treatments.